Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis
A high proportion of patients excluded from recombinant tissue plasminogen activator (rt-PA) treatment because of rapid improvement occurring before treatment decision had incomplete recovery. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trials dataset allows for systematic analyses of very early postrandomization improvement (VEPRIM) in stroke severity as a National Institutes of Health Stroke Scale (NIHSS) score was available for all subjects enrolled in the study at baseline (NIHSSB) and at 2 hours after randomization (NIHSS2H).
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Clotilde Balucani, Steven R. Levine, Jane C. Khoury, Pooja Khatri, Jeffrey L. Saver, Joseph P. Broderick Source Type: research
More News: Health | Ischemic Stroke | National Institutes of Health (NIH) | Neurology | Stroke | Study